TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23945719

Group type: EXPERIMENTAL
Intervention: Intervention to promote prolonged and exclusive breastfeeding
Number of subjects: 11867

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 11867
Study: 21169065

Group type: EXPERIMENTAL
Intervention: Hypothermia (cooled to 35°C until trauma assessment completed, then cooled to 33°C for 48 hours)
Number of subjects: 232

Group type: COMPARATOR
Intervention: Normothermia (treated at normothermia)
Number of subjects: 232
Study: 18299490

Group type: EXPERIMENTAL
Intervention: Traditional didactic decision aid
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Chronic disease trajectory model
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: Combination of both traditional decision aid and chronic disease trajectory model
Number of subjects: 611

Group type: COMPARATOR
Intervention: Public prostate cancer-specific Web sites (control condition)
Number of subjects: 611

Group type: EXPERIMENTAL
Intervention: All groups (including control)
Number of subjects: 611
Study: 17312857

Group type: EXPERIMENTAL
Intervention: Polymethoxyethylacrylate-coated circuits + leukocyte filters
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: Polypeptide-based heparin-bonded circuits with reduced heparinization
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control: uncoated circuits
Number of subjects: 270
Study: 12869172

Group type: EXPERIMENTAL
Intervention: IABC (Intra-Aortic Balloon Counterpulsation)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: IABC
Number of subjects: 30
Study: 11039338

Group type: EXPERIMENTAL
Intervention: 0.1 mmol/kg gadodiamide
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 0.2 mmol/kg gadodiamide
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: 0.3 mmol/kg gadodiamide
Number of subjects: 83
Study: 9200320

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8061123

Group type: EXPERIMENTAL
Intervention: Haemosorbtion on Ovosorb, a biospecific antiproteinase haemosorbent containing an immobilized ovomucoid
Number of subjects: 32
Study: 2972159

Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel alone (A)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel + 0.5 mg estriol (B)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: 0.030 mg ethinylestradiol + 0.15 mg desogestrel + 2 mg estriol (C)
Number of subjects: 19
Study: 238445

Group type: EXPERIMENTAL
Intervention: Flurazepam hydrochloride
Number of subjects: 0
Study: 30950894

Group type: EXPERIMENTAL
Intervention: Cyclotorsion compensated SMILE surgery (CC group: 54 eyes)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Standard SMILE surgery (S group: 30 eyes)
Number of subjects: 84
Study: 28385705

Group type: EXPERIMENTAL
Intervention: 3-year specialised treatment (extended early intervention)
Number of subjects: 160

Group type: COMPARATOR
Intervention: 2-year specialised treatment (step-down care)
Number of subjects: 160
Study: 25823909

Group type: EXPERIMENTAL
Intervention: 30 ml 0.3% silver nitrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 ml 0.5% silver nitrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 ml 0.3% silver nitrate
Number of subjects: 60
Study: 23097311

Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg/week) with methotrexate (combination)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: SC abatacept (125 mg/week) without methotrexate (monotherapy)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) with SC abatacept and methotrexate (combination)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Long-term extension (LTE) with SC abatacept without methotrexate (monotherapy)
Number of subjects: 100
Study: 22046727

Group type: EXPERIMENTAL
Intervention: VR integrated training (VR50)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional welding training (TW)
Number of subjects: 0
Study: 19019556

Group type: EXPERIMENTAL
Intervention: Early mechanical ventilation during the first 72 hours
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Total body surface area (BSA) burned
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Full-thickness BSA burned
Number of subjects: 851

Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 851

Group type: COMPARATOR
Intervention: Mechanism of injury
Number of subjects: 851

Group type: COMPARATOR
Intervention: Delay to ICBU admission
Number of subjects: 851
Study: 16484573

Group type: EXPERIMENTAL
Intervention: High-dose AGE (2.4 mL/d)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose AGE (0.16 mL/d)
Number of subjects: 51
Study: 15333470

Group type: EXPERIMENTAL
Intervention: Red meat intake (highest quintile)
Number of subjects: 37309

Group type: EXPERIMENTAL
Intervention: Processed meat intake (highest quintile)
Number of subjects: 37309

Group type: EXPERIMENTAL
Intervention: Total processed meat intake (≥5/week vs. <1/month)
Number of subjects: 37309

Group type: EXPERIMENTAL
Intervention: Bacon intake (≥2/week vs. <1/week)
Number of subjects: 37309

Group type: EXPERIMENTAL
Intervention: Hot dogs intake (≥2/week vs. <1/week)
Number of subjects: 37309
Study: 10658682

Group type: EXPERIMENTAL
Intervention: Grafts with BCR-ABL/ABL ratio <= 0.01
Number of subjects: 40

Group type: COMPARATOR
Intervention: Grafts with BCR-ABL/ABL ratio > 0.01
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Grafts with low levels of leukemic cell contamination
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Lowest level of contaminated stem cell collections (BCR-ABL/ABL ratio)
Number of subjects: 40
Study: 7722710

Group type: EXPERIMENTAL
Intervention: Atole (high-energy, high-protein supplement: 163 kcal/682 kJ and 6.4 g protein per serving)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Fresco (low-energy, no-protein supplement: 59 kcal/247 kJ per 180 mL)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Atole (for males aged 14-19 years)
Number of subjects: 364

Group type: COMPARATOR
Intervention: Fresco (for males aged 14-19 years)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Atole (for females aged 14-19 years)
Number of subjects: 364
Study: 2126727

Group type: EXPERIMENTAL
Intervention: Active nitroglycerin patches (10mg/24hrs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 16
Study: 7237200

Group type: EXPERIMENTAL
Intervention: Cimetidine 300 mg orally two hours pre-operatively
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sodium citrate 0.3 M solution 30 ml orally
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no agent to decrease gastric acidity)
Number of subjects: 45
Study: 30009626

Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Intervention (EIBI), 35 hours per week for 3 years.
Number of subjects: 94

Group type: COMPARATOR
Intervention: Standard early childhood services as usual (SAU).
Number of subjects: 94
Study: 31074598

Group type: EXPERIMENTAL
Intervention: Self-reported work-related injuries
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Self-reported musculoskeletal disorders
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Specific types of injuries
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Association with demographic variables
Number of subjects: 300
Study: 25927716

Group type: EXPERIMENTAL
Intervention: Electroconvulsive treatment (ECT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy volunteers not receiving ECT (Control Group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Patients undergoing electrical cardioversion (ECV) for atrial fibrillation (AF) (Control Group 2)
Number of subjects: 40
Study: 23702050

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (8 weekly sessions of 90 minutes each)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) (8 weekly sessions of 90 minutes each)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Waiting list (6 months)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Prolonged exposure and EMDR
Number of subjects: 240
Study: 20425129

Group type: EXPERIMENTAL
Intervention: Intravenous cannula stillete (IVCS)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional awl
Number of subjects: 45
Study: 19536452

Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and omeprazole (20 mg once daily) for 18 months
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 22
Study: 17366126

Group type: EXPERIMENTAL
Intervention: keepin' it REAL program
Number of subjects: 4622
Study: 14718679

Group type: EXPERIMENTAL
Intervention: Levodopa plus entacapone
Number of subjects: 300000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300000
Study: 11433128

Group type: EXPERIMENTAL
Intervention: Lisinopril 35mg (high dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lisinopril 5mg (low dose)
Number of subjects: 0
Study: 9622936

Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparins (LMWH) at home followed by oral anticoagulant
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unfractionated Heparin (UFH) in hospital followed by oral anticoagulant
Number of subjects: 0
Study: 9773138

Group type: EXPERIMENTAL
Intervention: Lidocaine infusion for 20 hours with a bolus dose before aortic clamping
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group without lidocaine infusion
Number of subjects: 100
Study: 2626338

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse, 15 ml, 3 times daily
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine mouthrinse
Number of subjects: 47
Study: 1107960

Group type: EXPERIMENTAL
Intervention: Topical application of ten units of regular insulin twice a day for five days
Number of subjects: 14

Group type: COMPARATOR
Intervention: Variety of topical therapies other than insulin
Number of subjects: 14
Study: 30940421

Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Surgery (S)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Continued smoking after RT
Number of subjects: 117
Study: 28542081

Group type: EXPERIMENTAL
Intervention: Dapivirine vaginal ring
Number of subjects: 2310

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2310
Study: 26431124

Group type: EXPERIMENTAL
Intervention: Intraarticular facet joint injections
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Best usual care
Number of subjects: 52
Study: 23872690

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 1495

Group type: COMPARATOR
Intervention: Implantable cardioverter-defibrillator (ICD) only
Number of subjects: 1495
Study: 22056634

Group type: EXPERIMENTAL
Intervention: High fear appeal
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Medium fear appeal
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Gain frame
Number of subjects: 321

Group type: COMPARATOR
Intervention: Low fear appeal
Number of subjects: 321

Group type: COMPARATOR
Intervention: Loss frame
Number of subjects: 321

Group type: COMPARATOR
Intervention: Education (control group)
Number of subjects: 321

Group type: COMPARATOR
Intervention: Non-education (control group)
Number of subjects: 321
Study: 19483278

Group type: EXPERIMENTAL
Intervention: Phosphate binders
Number of subjects: 0
Study: 17110816

Group type: EXPERIMENTAL
Intervention: Intravenous glycine infusion
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 13
Study: 15243887

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Balloon Dilation (EPBD)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (EST)
Number of subjects: 200
Study: 11302905

Group type: EXPERIMENTAL
Intervention: Near patient testing for H pylori and open access endoscopy for patients with positive results
Number of subjects: 478

Group type: COMPARATOR
Intervention: Acid suppressing drugs or specialist referral at general practitioner's discretion
Number of subjects: 478
Study: 9287573

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Nurse-controlled analgesia (NCA)
Number of subjects: 66
Study: 8346946

Group type: EXPERIMENTAL
Intervention: 100 U/kg r‐HuEpo subcutaneously three times a week from week 3 to week 7
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (15 infants)
Number of subjects: 29
Study: 3953477

Group type: EXPERIMENTAL
Intervention: dl‐alpha‐tocopheryl acetate (all‐rac‐alpha‐tocopheryl acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: d‐alpha‐tocopheryl acetate (RRR‐alpha‐tocopheryl acetate)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both forms of vitamin E
Number of subjects: 0
Study: 31672387

Group type: EXPERIMENTAL
Intervention: LAI‐risperidone (LAI‐R)
Number of subjects: 305

Group type: COMPARATOR
Intervention: daily oral second‐generation antipsychotics (SGA)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Emotional withdrawal
Number of subjects: 305
Study: 29605716

Group type: EXPERIMENTAL
Intervention: Autologous stem cell transplantation (ASCT)
Number of subjects: 162

Group type: COMPARATOR
Intervention: No transplant
Number of subjects: 162
Study: 27564579

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC) for 60–90 seconds
Number of subjects: 200

Group type: COMPARATOR
Intervention: Umbilical cord milking (UCM)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Delayed cord clamping (DCC)
Number of subjects: 200
Study: 23765630

Group type: EXPERIMENTAL
Intervention: Netupitant 50 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netupitant 100 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Netupitant 200 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 23036028

Group type: EXPERIMENTAL
Intervention: Geriatric Evaluation and Management Unit (GEMU) care
Number of subjects: 99

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 99
Study: 19287303

Group type: EXPERIMENTAL
Intervention: Transdermal testosterone (300 microg twice weekly)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 17452090

Group type: EXPERIMENTAL
Intervention: Dietary supplements to lower homocysteine
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Test-retest data with a 1-year interval
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Full sample analysis
Number of subjects: 253

Group type: EXPERIMENTAL
Intervention: Age stratification
Number of subjects: 253
Study: 15118196

Group type: EXPERIMENTAL
Intervention: CordyMax Cs-4 (3 g/d)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 22
Study: 11486455

Group type: EXPERIMENTAL
Intervention: Eberconazole 1% cream
Number of subjects: 157

Group type: COMPARATOR
Intervention: Clotrimazole 1% cream
Number of subjects: 157
Study: 9571333

Group type: EXPERIMENTAL
Intervention: Intensive therapy (insulin therapy alone)
Number of subjects: 153

Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 153
Study: 8153573

Group type: EXPERIMENTAL
Intervention: 0.1% delmopinol HCl
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5% delmopinol HCl
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1% delmopinol HCl
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 3360731

Group type: EXPERIMENTAL
Intervention: Methylphenidate
Number of subjects: 1

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1
Study: 7238679

Group type: EXPERIMENTAL
Intervention: Visual signals presented at two spatial locations (15.5 degrees and 29.1 degrees)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual signals presented with room illumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual signals presented without room illumination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual stimulus triggering eye-hand-arm motion
Number of subjects: 0
Study: 31220010

Group type: EXPERIMENTAL
Intervention: Stretching and progressive resistance exercise for lower extremities for 16 weeks, followed by a 16-week maintenance program
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (comparison group)
Number of subjects: 37
Study: 28864699

Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade with a condom-catheter device and misoprostol
Number of subjects: 116

Group type: COMPARATOR
Intervention: Misoprostol alone (control)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Uterine balloon tamponade with misoprostol
Number of subjects: 116
Study: 26485379

Group type: EXPERIMENTAL
Intervention: Counseling for behavioral changes (group 1)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Counseling and an occlusal appliance (group 2)
Number of subjects: 41
Study: 23864781

Group type: EXPERIMENTAL
Intervention: Novel double pants (NDP)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Conventional single pants (CSP)
Number of subjects: 160
Study: 22858075

Group type: EXPERIMENTAL
Intervention: ADR + carvedilol
Number of subjects: 50

Group type: COMPARATOR
Intervention: ADR
Number of subjects: 50
Study: 19683115

Group type: EXPERIMENTAL
Intervention: Crystal Light Lemonade
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tropical Punch Kool‐Aid
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Tropicana orange juice
Number of subjects: 23

Group type: COMPARATOR
Intervention: Water
Number of subjects: 23
Study: 17478154

Group type: COMPARATOR
Intervention: Endothelium-dependent (flow-mediated dilation [FMD]) in patients with AF
Number of subjects: 46

Group type: COMPARATOR
Intervention: Endothelium-independent (nitroglycerin-mediated dilation [NMD]) in patients with AF
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FMD after restoration of sinus rhythm at 24 hours
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: FMD after restoration of sinus rhythm at 1 month
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: NMD after restoration of sinus rhythm at 24 hours
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: NMD after restoration of sinus rhythm at 1 month
Number of subjects: 46
Study: 15632861

Group type: EXPERIMENTAL
Intervention: Loratidine 10 mg daily for 7 days (group A)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Loratidine 10 mg daily for 7 days (group B)
Number of subjects: 20
Study: 11165950

Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 14 days, followed by placebo for 42 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 14 days, followed by elemental calcium 1000 mg/day and placebo for 14 days, then by placebo for 28 days
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Risedronate 20 mg/day for 7 days, followed by elemental calcium 1000 mg/day and placebo for 21 days, then risedronate 20 mg/day for 7 days, and finally elemental calcium 1000 mg/day and placebo for 21 days
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo for 56 days
Number of subjects: 32
Study: 9708956

Group type: EXPERIMENTAL
Intervention: Apolipoprotein E ε4 carriers
Number of subjects: 405

Group type: COMPARATOR
Intervention: Noncarriers of apoE ε4
Number of subjects: 405
Study: 8069001

Group type: EXPERIMENTAL
Intervention: Interferon beta‐1b (IFN beta ser)
Number of subjects: 372
Study: 2742099

Group type: EXPERIMENTAL
Intervention: Buprenorphine 2.5 micrograms/kg intravenously
Number of subjects: 40

Group type: COMPARATOR
Intervention: Saline (placebo) administered intravenously 8 minutes before induction
Number of subjects: 40
Study: 951476

Group type: EXPERIMENTAL
Intervention: Isolation condition (air fluidized, ceramic bead bed in a light attenuating chamber)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Non isolation condition
Number of subjects: 40
Study: 30736402

Group type: EXPERIMENTAL
Intervention: REHIT
Number of subjects: 32

Group type: COMPARATOR
Intervention: MICT
Number of subjects: 32
Study: 28661955

Group type: EXPERIMENTAL
Intervention: STM+UC
Number of subjects: 100

Group type: COMPARATOR
Intervention: UC
Number of subjects: 100
Study: 26618458

Group type: EXPERIMENTAL
Intervention: 3 times injection with 4 cc dose
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 times injection with 6 cc dose
Number of subjects: 24
Study: 22995453

Group type: EXPERIMENTAL
Intervention: 100 mg/kg of EACA after induction, upon initiation of CPB, and after protamine.
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 75 mg/kg of EACA after induction, followed by a maintenance infusion of 75 mg/kg/h until chest closure, and an additional 75 mg/kg upon initiation of CPB.
Number of subjects: 120

Group type: COMPARATOR
Intervention: No antifibrinolytic agent or placebo (Control Group).
Number of subjects: 120
Study: 21321298

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 4922

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 4922
Study: 19419824

Group type: EXPERIMENTAL
Intervention: Prone position
Number of subjects: 32

Group type: COMPARATOR
Intervention: Supine position
Number of subjects: 32
Study: 17178496

Group type: COMPARATOR
Intervention: Podophyllin resin (25%)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Podophyllin resin (25%) together with acyclovir cream (5%)
Number of subjects: 46
Study: 15095843

Group type: EXPERIMENTAL
Intervention: Dideco DHF0.2
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Minntech Hemocor HPH 400
Number of subjects: 10
Study: 11430636

Group type: EXPERIMENTAL
Intervention: Tofranil 25
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Tofranil mite (10 mg)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aqueous solution containing 25 mg imipramine-HCl
Number of subjects: 18
Study: 9552905

Group type: EXPERIMENTAL
Intervention: Point of care testing
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Point of care testing for haematological tests
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Point of care testing for biochemical tests
Number of subjects: 1728

Group type: EXPERIMENTAL
Intervention: Point of care testing for analyses of arterial blood gases
Number of subjects: 1728
Study: 7512659

Group type: EXPERIMENTAL
Intervention: Serum prostate specific antigen (PSA)
Number of subjects: 6630

Group type: EXPERIMENTAL
Intervention: Digital rectal examination
Number of subjects: 6630

Group type: EXPERIMENTAL
Intervention: Combination of PSA and digital rectal examination
Number of subjects: 6630

Group type: EXPERIMENTAL
Intervention: PSA
Number of subjects: 6630